EVELYN DUMKWU: Open Payments
NPI 1487360756 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$417 in 19 payments from 7 companies in 2025. Trend: 2023 $914 · 2024 $1,432 · 2025 $417
Food & beverage: $417
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $97 |
| ABBVIE INC. | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $54 |
| Neurocrine BioSciences, Inc. | 2 | $50 |
| Alkermes, Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $34 |
Products named: VRAYLAR, UZEDY, REXULTI, CAPLYTA, INGREZZA, Auvelity, ARISTADA, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
